S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
BREAKING: Tiny biotech successfully treats blindness (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
BREAKING: Tiny biotech successfully treats blindness (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
BREAKING: Tiny biotech successfully treats blindness (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
BREAKING: Tiny biotech successfully treats blindness (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
BREAKING: Tiny biotech successfully treats blindness (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
BREAKING: Tiny biotech successfully treats blindness (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
BREAKING: Tiny biotech successfully treats blindness (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
BREAKING: Tiny biotech successfully treats blindness (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
Top-Rated StocksTop-RatedMost-Upgraded StocksMost-Upgraded
NASDAQ:SRPT

Sarepta Therapeutics (SRPT) Earnings Date, Estimates & Call Transcripts

$126.82
-2.04 (-1.58%)
(As of 05/26/2023 08:47 PM ET)
Compare
Today's Range
$126.41
▼
$129.67
50-Day Range
$120.20
▼
$157.19
52-Week Range
$61.28
▼
$159.89
Volume
1.34 million shs
Average Volume
1.54 million shs
Market Capitalization
$11.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$169.65
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Aug. 1Estimated
Actual EPS
(May. 2)
-$0.97 Beat By $0.49
Consensus EPS
(May. 2)
-$1.46
Last Year's Q2 EPS
(5/4/2022)
-$1.20
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

SRPT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SRPT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Sarepta Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20233($2.29)($1.41)($1.76) 
Q2 20233($2.85)($1.53)($2.10) 
Q3 20233($2.30)($1.45)($1.93) 
Q4 20233($1.38)($1.15)($1.26) 
FY 202312($8.82)($5.54)($7.05) 
Q1 20243($1.45)($0.32)($0.83) 
Q2 20243($1.32)$0.22($0.56) 
Q3 20243($0.48)$1.16$0.47 
Q4 20243$0.56$3.03$1.95 
FY 202412($2.69)$4.09$1.03 
Q1 20251$0.95$0.95$0.95 

SRPT Earnings Date and Information

Sarepta Therapeutics last posted its earnings results on May 2nd, 2023. The biotechnology company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.46) by $0.49. The firm had revenue of $253.50 million for the quarter, compared to the consensus estimate of $241.47 million. Its quarterly revenue was up 20.2% on a year-over-year basis. Sarepta Therapeutics has generated ($12.69) earnings per share over the last year (($12.69) diluted earnings per share). Earnings for Sarepta Therapeutics are expected to grow in the coming year, from ($10.81) to $1.97 per share. Sarepta Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 1st, 2023 based off prior year's report dates.

Sarepta Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/1/2023
(Estimated)		        
5/2/2023Q1 23($1.46)($0.97)+$0.49$2.98$241.47 million$253.50 million    
2/28/2023Q4 22($1.28)($1.24)+$0.04($1.24)$250.51 million$258.43 million    
11/2/2022Q3 2022($1.21)($2.94)($1.73)($2.94)$234.55 million$230.30 million    
8/2/2022Q2 2022($1.07)($2.65)($1.58)($2.65)$220.08 million$233.49 million
5/4/2022Q1 2022($1.35)($1.20)+$0.15($1.20)$208.25 million$210.83 million    
3/1/2022Q4 2021($1.51)($1.42)+$0.09($1.42)$198.48 million$201.50 million    
11/3/20219/30/2021($1.86)($0.60)+$1.26($0.60)$170.13 million$189.41 million    
8/4/20216/30/2021($1.29)($1.02)+$0.27($1.02)$161.95 million$164.09 million    
5/5/20213/31/2021($2.01)($2.10)($0.09)($2.10)$140.73 million$146.93 million  
3/1/202112/31/2020($1.99)($2.40)($0.41)($2.40)$145.54 million$145.10 million  
11/5/20209/30/2020($1.89)($2.50)($0.61)($2.50)$133.69 million$143.92 million  
8/5/20206/30/2020($1.73)($1.93)($0.20)($1.93)$112.36 million$137.36 million  
5/6/20203/31/2020($2.17)($0.23)+$1.94($0.23)$118.18 million$113.67 million  
2/26/2020Q4 2019($1.86)($3.16)($1.30)($3.16)$100.10 million$100.11 million  
11/7/2019Q3 19($1.35)($1.70)($0.35)($1.70)$98.49 million$99.04 million  
8/7/2019Q2 19($1.08)($3.74)($2.66)($3.74)$91.05 million$94.67 million  
5/8/20193/31/2019($2.05)($1.07)+$0.98($1.07)$86.92 million$87.01 million  
2/27/2019Q4 2018($1.08)($2.05)($0.97)($2.05)$84.83 million$84.40 million  
10/24/20189/30/2018($0.86)($1.15)($0.29)($1.15)$78.84 million$78.49 million  
8/8/2018Q2 2018($0.68)($1.67)($0.99)$0.35$71.53 million$73.53 million
5/3/2018Q1 2018($0.32)($0.55)($0.23)($0.33)$65.31 million$64.60 million
3/1/2018Q4 2017($0.32)($0.37)($0.05)($0.37)$57.33 million$57.30 million  
10/25/2017Q3 2017($0.86)($0.20)+$0.66($0.78)$41.29 million$45.95 million
7/19/2017Q2 2017($0.92)($0.46)+$0.46($1.15)$22.52 million$35.01 million
4/27/2017Q1 2017($0.85)($0.73)+$0.12($2.96)$13.80 million$16.34 million
2/28/2017Q4 2016($1.26)($1.58)($0.32)($1.54)$4.86 million$5.42 million  
10/27/2016Q3 2016($1.35)($1.18)+$0.17($1.18)$1.06 million  
7/19/2016Q2 2016($1.19)($1.35)($0.16)($1.35)$1.10 million
5/5/2016Q1 2016($1.30)($1.31)($0.01)($1.31)$0.18 million
2/25/2016Q4 2015($1.20)($1.44)($0.24)($1.44)$1.25 million
11/5/2015Q3 2015($1.19)($1.25)($0.06)($1.25)  
8/6/2015Q2 2015($1.21)($1.01)+$0.20($1.01)$0.31 million$0.01 million  
5/7/2015Q1 2015($1.00)($1.49)($0.49)($1.49)$0.78 million  
2/26/2015Q4 2014($0.83)($1.08)($0.25)($1.08)$1.56 million$0.30 million  
11/6/2014Q3 2014($0.95)($0.71)+$0.24($0.71)$3.07 million$1.10 million  
8/7/2014Q2 2014($0.78)($0.85)($0.07)($0.85)$4.30 million$2.58 million  
5/8/2014Q1 2014($0.80)($0.75)+$0.05($0.75)$3.45 million$6.09 million  
2/27/2014Q4 2013($0.70)($0.23)+$0.47($0.23)$4.53 million$2.60 million  
11/12/2013Q3 2013($0.66)($0.73)($0.07)($0.22)$4.57 million$4.20 million  
8/8/2013Q2 2013($0.72)($0.60)+$0.12($0.60)$5.08 million$3.00 million  
5/9/2013Q1 2013($0.55)($0.46)+$0.09$0.40$5.85 million$4.50 million  
3/7/2013Q4 2012($0.26)($2.36)($2.10)$6.71 million$7.30 million  
11/7/2012($0.27)($2.17)($1.90)$10.06 million$7.57 million
8/7/2012Q2 2012($0.29)($0.24)+$0.05($0.84)
5/10/2012Q1 2012($0.42)($0.30)+$0.12$0.18
3/1/2012Q4 2011($0.36)($0.06)+$0.30($0.06)
11/3/2011Q3 2011($0.30)($0.18)+$0.12($0.18)
8/4/2011Q2 2011($0.42)$0.05+$0.47$0.05
5/5/2011Q1 2011($0.18)$0.12+$0.30$0.12
3/10/2011Q4 2010($0.42)($0.41)+$0.01($0.41)
11/9/2010Q3 2010($0.36)($0.42)($0.06)($0.42)
8/9/2010Q2 2010($0.30)($0.91)($0.61)($0.91)
5/10/2010Q1 2010($0.24)($0.03)+$0.21($0.03)
3/16/2010Q4 2009($0.36)$0.18+$0.54$0.18
11/9/2009Q3 2009($0.42)($0.48)($0.06)($0.48)
8/10/2009Q2 2009($0.12)($0.36)($0.24)$0.66
5/11/2009Q1 2009($0.18)($0.07)+$0.11($0.07)
3/10/2009Q4 2008($0.30)($0.10)+$0.20($0.10)
11/10/2008Q3 2008($0.42)($0.50)($0.08)($0.50)
8/11/2008Q2 2008($0.42)($0.14)+$0.28($0.14)
5/12/2008Q1 2008($0.78)($0.47)+$0.31$0.44
3/12/2008Q4 2007($0.45)($0.45)($0.45)












Sarepta Therapeutics Earnings - Frequently Asked Questions

When is Sarepta Therapeutics's earnings date?

Sarepta Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 1st, 2023 based off last year's report dates. Learn more on SRPT's earnings history.

Did Sarepta Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Sarepta Therapeutics (NASDAQ:SRPT) reported ($0.97) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.46) by $0.49. Learn more on analysts' earnings estimate vs. SRPT's actual earnings.

How can I listen to Sarepta Therapeutics's earnings conference call?

The conference call for Sarepta Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Sarepta Therapeutics's conference call transcript?

The conference call transcript for Sarepta Therapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Sarepta Therapeutics generate each year?

Sarepta Therapeutics (NASDAQ:SRPT) has a recorded annual revenue of $933.01 million.

How much profit does Sarepta Therapeutics generate each year?

Sarepta Therapeutics (NASDAQ:SRPT) has a recorded net income of -$703.49 million. SRPT has generated -$12.69 earnings per share over the last four quarters.

What is Sarepta Therapeutics's EPS forecast for next year?

Sarepta Therapeutics's earnings are expected to grow from ($10.81) per share to $1.97 per share in the next year.

More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:SRPT) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -